ADJUNCTIVE ZIPRASIDONE IN OVERWEIGHT AND OBESE PATIENTS WITH BIPOLAR DISORDER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将评估超重和肥胖患者在改用其他以前使用的药物后，接受辅助性齐拉西酮治疗后胰岛素敏感性和血脂的相关变化。这项研究将与齐拉西酮的单独治疗研究一起进行。口服葡萄糖耐量试验将在基线和齐拉西酮12周试验结束时进行。研究人员希望收集肥胖和超重双相情感障碍患者的胰岛素敏感性和血脂信息，这些患者从与体重增加相关的药物(即奥氮平、利培酮、奎硫平、阿立哌唑、锂或丙戊酸盐)转向被认为更中性的药物(齐拉西酮)。到目前为止，尚不清楚与治疗相关的体重变化是否与胰岛素抵抗、糖耐量、血脂异常和其他胰岛素抵抗综合征症状的变化有关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research study will evaluate treatment-associated changes in insulin sensitivity and blood lipids in overweight and obese patients receiving adjunctive ziprasidone, following a switch from other previously used medications. This study will be conducted in conjunction with a separate treatment study of ziprasidone. Oral glucose tolerance testing will be conducted at baseline and at the end of a 12-week trial of ziprasidone. The investigators hope to gather information on insulin sensitivity and blood lipids in obese and overweight bipolar patients who switch from medications associated with weight gain (i.e. olanzapine, risperidone, quetiapine, aripiprazole, lithium, or valproate) to one thought to be more weight-neutral (ziprasidone). To date, it is unclear whether treatment-associated changes in body weight are related to changes in insulin resistance, glucose tolerance, dyslipidemia, and other symptoms of insulin resistance syndrome.